Found: 6
Select item for more details and to access through your institution.
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
- Published in:
- Science Translational Medicine, 2022, v. 14, n. 635, p. 1, doi. 10.1126/scitranslmed.abl8124
- By:
- Publication type:
- Article
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.
- Published in:
- Science Translational Medicine, 2024, v. 16, n. 753, p. 1, doi. 10.1126/scitranslmed.ado2817
- By:
- Publication type:
- Article
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31615-7
- By:
- Publication type:
- Article
Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma.
- Published in:
- 1996
- By:
- Publication type:
- journal article
Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
- Published in:
- PLoS ONE, 2017, v. 12, n. 11, p. 1, doi. 10.1371/journal.pone.0188708
- By:
- Publication type:
- Article